Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | PGK1 | P00558 | 4/20 | 0.38 |
| ▸ | PGK2 | P07205 | 4/20 | 0.38 |
| ▸ | ESR1 | P03372 | 6/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23908217 | 0.92 | PGK1 (0.43) | PGK1PGK2ESR1ESR2PTPN5 | |
| SCHEMBL3390400 | 0.80 | PGK1 (0.52) | GABRA1GABRB2PGK1PGK2PTPN5 | |
| SCHEMBL7870277 | 0.79 | PGK1 (0.44) | PGK1PGK2ESR1ESR2PTPN5 | |
| SCHEMBL39365 | 0.78 | LMNA (0.46) | MEN1KMT2ACYP3A4 | |
| SCHEMBL3803728 | 0.77 | LMNA (0.35) | PGK1PGK2ESR1ESR2PTPN5 | |
| SCHEMBL4609991 | 0.76 | KDM4E (0.40) | KMT2AKDM4E | |
| SCHEMBL11762641 | 0.74 | PTPN1 (0.52) | PGK1PGK2ESR1ESR2AR | |
| SCHEMBL11763736 | 0.74 | PGK1 (0.42) | PGK1PGK2MEN1KMT2AFDPS | |
| SCHEMBL5859053 | 0.73 | PTPN5 (0.46) | PGK1PGK2ESR1ESR2PTPN5 | |
| SCHEMBL1556937 | 0.73 | PTPN1 (0.52) | PGK1PGK2PTPN5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410116-B2 | Bis(styryl)pyrimidine or bis(styryl)benzene compounds, pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for prevention or treatment of diseases featuring amyloids comprising the same as an active ingredient | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-04-02 | — | — | US | disclosed |
| US-20100190803-A1 | BIS(STYRYL)PYRIMIDINE OR BIS(STYRYL)BENZENE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES FEATURING AMYLOIDS COMPRISING THE SAME AS AN ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190803-A1 | BIS(STYRYL)PYRIMIDINE OR BIS(STYRYL)BENZENE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES FEATURING AMYLOIDS COMPRISING THE SAME AS AN ACTIVE INGREDIENT | PSEN1, APP, BACE1 | GABRA1 141/4885GABRB2 283/4885PGK1 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.